TransThera Biosciences Initiates First Human Dose of TT-00920, a Novel PDE9 inhibitor for Chronic Heart Failure Treatment

NANJING, China, March 7, 2020 -- TransThera Biosciences Co. Ltd, a clinical-stage biotechnology company based in Nanjing, China, today announced that the first cohort of healthy volunteers has been dosed in Phase 1 clinical trial with TT-00920, a novel Phosphodiesterase 9 (PDE 9) inhibitor in development for the treatment of chronic heart failure. 

The double-blind, placebo-controlled, single and multiple ascending dose trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TT-00920 in healthy volunteers and will also include the evaluation of food effects. 

Dr. Frank Wu, TransThera’s founder and CEO said, “The dosing of the first healthy volunteer with TT-00920 is a significant milestone for the company. We are very excited to begin the development of this important clinical candidate intended to treat chronic heart failure, which is an area of tremendous unmet medical need. We look forward to the results of the studies. We are grateful to the efforts of our project team and clinical collaborators.” 

TT-00920 is an investigational, highly potent and selective PDE9 inhibitor for the treatment of chronic heart failure. PDE9 protein interferes with a body’s natural "braking" system needed to neutralize stress on the heart and has shown to be markedly elevated in heart failure, particularly in HFpEF. Inhibiting PDE9 with TT-00920 restores the cardio-protective mechanism that is dysfunctional in heart failure. Compelling preclinical data demonstrates that TT-00920 strongly enhanced cardiac function and reversed ventricular remodeling in heart failure.

About Heart Failure
Chronic heart failure (CHF) is a chronic, progressive clinical syndrome that results from structural or functional impairment of ventricular filling or ejection of blood. It is a global problem with increasing prevalence due to an aging population worldwide with increasing co-morbidities. The current global prevalence of heart failure is estimated to be more than 26 million people. While current therapies have helped to improve patient outcomes, CHF remains the leading cause of hospitalization for those over the age of 65 and represents a significant clinical and economic burden.

About TransThera Biosciences
TransThera Biosciences, founded in 2016, is a clinical-stage biotechnology company dedicated to developing innovative therapeutics to target diseases with major unmet medical needs, including cancer, cardiovascular, and inflammatory diseases. TT-00920 marks the companys second innovative drug candidate entering global clinical development. For more information, please visit